Gene-editing, and targeting capabilities of components of gene-editing systems, can be harnessed to provide wide-ranging, practical applications, yet freedom to operate issues often pose ongoing challenges for pioneers and start-ups in this fast-moving, powerful field.  

Whilst there is immense focus on CRISPR gene-editing, older techniques continue to have applications, with the early systems providing impetus for further developments in genetic modification in the CRISPR field and beyond.  

HGF has one of the most experienced, commercially- minded teams in Europe focussed on gene-editing, with significant experience of involvement in European oppositions affecting the foundational CRISPR IP,  as well as advising on and patenting earlier gene-editing systems, such as TALENs.  

The core team of specialists that make-up the HGF CRISPR team are backed by a larger group of over 75 patent attorneys and solicitors, with backgrounds in life sciences, pharmaceuticals, chemistry and plant sciences.  

Specialising in gene-editing in the context of new human and animal therapies, viral diagnostics, developments in animal farming and microbiome, as well as plant protection and breeding, the HGF CRISPR team includes specialists from the firm’s AgBio team. This enables HGF to develop multidisciplinary IP strategies across this important and complex field.  

HGF works with pioneers of CRISPR technology, as well as for clients advancing the field of gene modification and applications of CRISPR, to those that endeavour to resolve important problems, such as antibiotic resistance and infection diagnostics. This wealth of expertise sees HGF attorneys conducting talks at international events and providing articles on IP developments in the fast-evolving CRISPR field, along with the broader genetic engineering sector.